Theravance Biopharma, Inc. (TBPH) Form 8-K — Aug 10, 2026
Theravance Biopharma reported Q2 2026 revenue of $20.7 million, up 11% year-over-year, driven entirely by Viatris collaboration revenue on YUPELRI. GAAP net loss was $5.9 million versus prior-year net income of $54.8 million, which included a one-time $75.1 million gain on the sale of its TRELEGY royalty interests. Underlying operations improved sharply: non-GAAP net income from operations swung to $9.5 million from a $4.2 million loss a year ago, and operating expenses fell 35% year-over-year following the restructuring announced after the March 2026 CYPRESS Phase 3 results.
Key figures
- Revenue
- 20731000
- Revenue Yoy
- 11% (Viatris collaboration revenue)
- Total Assets
- 469770000
- Cash Position
- 387657000
- Shares Outstanding
- 51890754
- Debt
- no debt
- Cvr terms
- 80% of net proceeds from any ampreloxetine license, divestiture or monetization over ten years
- Rd expenses q2
- 4712000
- Sga expenses q2
- 14176000
- Six month revenue
- 38430000
- Opex reduction yoy
- 35% (excluding restructuring and transaction costs)
- Shareholders equity
- 289705000
- Run rate cost savings
- approximately $70 million expected 2H 2026
- Yupelri net sales yoy
- 7%
- Planned opex reduction
- approximately 60% vs 2025 actuals of $111.1 million
- Restructuring expenses q2
- 4031000
- Hospital channel doses yoy
- 25%
- Acquisition price per share
- 17
- Yupelri customer demand yoy
- 10%
- Transaction related expenses q2
- 6089000
- Trelegy fy2025 global net sales
- approximately $3.9 billion
- Annualized cash flow expectation
- $60-70 million (excluding restructuring and transaction costs)
- Trelegy q2 2026 global net sales
- approximately $1.0 billion
- Prior year q2 gain on royalty sale
- 75137000
- Trelegy fy2026 milestone threshold
- approximately $3.5 billion (triggers $100M Royalty Pharma payment)
- Yupelri q2 net sales viatris recorded
- 70666000
- Non gaap net income from operations q2
- 9467000
Price after filing
Close on the filing date to close N calendar days later (from $16.93). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.